GLP-1 Savings Programs That Actually Work: A Complete Guide to Affordable Weight Loss Medication

If you've been prescribed a GLP-1 medication for weight loss or diabetes management, you've probably experienced sticker shock at the pharmacy counter. With brand-name options like Ozempic, Wegovy, and Mounjaro costing upward of $1,000 per month without insurance, many people who could benefit from these medications simply can't afford them. But here's the good news: several legitimate savings programs and alternatives exist that can dramatically reduce your out-of-pocket costs.

Let's walk through the options that actually work, so you can make an informed decision about accessing this breakthrough class of medications.

Understanding Why GLP-1 Medications Are So Expensive

GLP-1 receptor agonists represent years of pharmaceutical research and development. Brand-name versions like Ozempic (semaglutide) and Mounjaro (tirzepatide) are still under patent protection, meaning generic versions aren't yet available in the traditional sense.

Most insurance plans cover these medications for diabetes management, but coverage for weight loss remains inconsistent. Even with insurance, copays can range from $25 to several hundred dollars monthly, depending on your plan.

This creates a significant access problem, particularly for women between 30 and 60 who represent the largest demographic seeking GLP-1 therapy for weight management and metabolic health.

Manufacturer Savings Programs: Your First Stop

Each major GLP-1 manufacturer offers savings cards and patient assistance programs, though they come with specific eligibility requirements.

Novo Nordisk Savings Card (Ozempic & Wegovy)

Novo Nordisk offers savings cards that can reduce your monthly cost to as low as $25 if you have commercial insurance. The catch? These cards specifically exclude government insurance like Medicare and Medicaid.

For Wegovy specifically, Novo Nordisk's WeGoTogether program provides savings for eligible patients with commercial insurance. Uninsured patients may qualify for the Patient Assistance Program, which provides free medication based on income requirements.

Eli Lilly Savings Card (Mounjaro & Zepbound)

Eli Lilly's savings card can reduce Mounjaro costs to $25 per month for commercially insured patients. For Zepbound (the weight loss indication), similar savings apply through their savings card program.

Lilly also offers the Lilly Cares Foundation Patient Assistance Program for uninsured or underinsured individuals who meet income guidelines.

The Fine Print Matters

Most manufacturer savings programs require commercial insurance and specifically exclude Medicare, Medicaid, and other government programs. They're typically valid for 12-24 months, and eligibility can change based on your insurance status.

Alternative Paths to Affordable GLP-1 Therapy

Compounded Semaglutide and Tirzepatide

Compounded versions of GLP-1 medications have emerged as a legitimate and significantly more affordable option. Licensed compounding pharmacies create these medications using the same active ingredients as brand-name versions.

These compounded medications are legal under FDA guidelines during drug shortage periods and when prescribed by licensed physicians. They typically cost between $99 and $300 per month, making them accessible to patients who don't qualify for manufacturer programs or who lack insurance coverage.

The quality and safety of compounded medications depend entirely on the pharmacy's accreditation and adherence to proper compounding standards. Look for pharmacies that are FDA-registered and follow USP 797 guidelines.

Telehealth GLP-1 Programs

Telehealth platforms have revolutionized access to GLP-1 therapy by combining virtual medical consultations with compounded medications at transparent, flat-rate pricing. This model eliminates the insurance maze entirely and often proves more affordable than traditional routes, even with insurance.

These programs typically include medical oversight, prescription management, and medication delivery, creating a comprehensive care experience at a predictable monthly cost.

Insurance Navigation Strategies

If you have commercial insurance, don't assume your GLP-1 medication isn't covered. Coverage policies change frequently as insurers recognize the long-term health benefits and cost savings of treating obesity and metabolic conditions.

Prior Authorization Tips

Your doctor can submit a prior authorization that documents medical necessity. This works best when your prescription includes documented conditions like prediabetes, fatty liver disease, or cardiovascular risk factors alongside elevated BMI.

Some insurers cover GLP-1s for diabetes (like Ozempic for type 2 diabetes) but not for weight loss (like Wegovy), even though they contain the same active ingredient. Your physician may be able to prescribe strategically based on your specific health conditions.

Appeal Denials

If your insurance denies coverage, you have the right to appeal. Your healthcare provider can submit additional documentation highlighting medical necessity, previous weight loss attempts, and obesity-related health complications.

Gender Considerations in GLP-1 Costs and Access

Women face unique challenges in accessing affordable GLP-1 therapy. Research shows women are more likely to be uninsured or underinsured, and obesity medications have historically been dismissed as cosmetic rather than medical necessities.

Women also experience higher rates of obesity-related conditions like PCOS, hormonal imbalances, and thyroid disorders that can benefit from GLP-1 therapy. Yet insurance coverage for weight management remains frustratingly inconsistent compared to coverage for traditionally male-dominated conditions.

Men seeking GLP-1 therapy may find easier insurance approval when prescriptions emphasize metabolic conditions, cardiovascular risk, or type 2 diabetes rather than weight loss alone.

What Doesn't Work: Savings Pitfalls to Avoid

Not all savings programs deliver on their promises. Be cautious of international pharmacies offering dramatically discounted GLP-1s, as medication authenticity and safety cannot be verified.

Sharing or splitting doses with others is dangerous and illegal. GLP-1 medications require specific dosing protocols and medical supervision to ensure safety and effectiveness.

Some discount pharmacy cards claim to reduce costs but may not work with controlled or specialty medications like GLP-1s. Always verify the program works specifically for your medication before counting on savings.

From the Ozari Care Team

The most important factor in successful GLP-1 therapy isn't just finding an affordable option—it's ensuring you have proper medical supervision throughout your treatment journey. Cost-saving measures should never compromise the quality of your medical care or the safety of your medication. We recommend choosing savings programs that include ongoing physician oversight, so your dosing can be adjusted as needed and potential side effects can be managed appropriately.

Making GLP-1 Therapy Affordable and Accessible

The landscape of GLP-1 savings programs continues to evolve. While brand-name medications remain expensive, legitimate pathways to affordable treatment exist through manufacturer programs, compounded alternatives, and telehealth platforms.

The key is understanding your specific situation: your insurance status, income level, medical conditions, and treatment goals. For many people, especially those without insurance or with high deductibles, compounded GLP-1 medications through reputable telehealth platforms offer the most straightforward and affordable path to treatment.

At Ozari Health we offer compounded Semaglutide and Tirzepatide as low as $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically Reviewed — Ozari Clinical Content Team (OCCT). Health writers and wellness professionals specializing in GLP-1 therapy, metabolic health, and weight loss medicine. Content reviewed in accordance with Ozari's Editorial Standards. Last reviewed: April 25, 2026.

This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

Last reviewed: April 25, 2026